UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 117, 2011

ARYx THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-33782	77-0456039
(State or other jurisdiction	(Commission File Number)	(IRS Employer Identification No.)
of incorporation)

6300 Dumbarton Circle

Fremont, California

94555

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (510) 585-2200

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 58.0201. ~~Departure~~Other ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Events.

On February 117, 2011, ~~Keith Leonard resigned as a member of~~ our board of directors, or the Board, ~~including~~appointed asLars aEkman ~~member~~to of the Audit Committee of the Board, ~~and~~or ~~Nominating~~the ~~and~~Audit ~~Corporate~~Committee. Dr. Ekman’s ~~Governance~~appointment to the Audit Committee offills the ~~Board,~~vacancy ~~effective~~created ~~immediately~~by the resignation of Keith Leonard on February 1, 2011. MrThe Board has determined that Dr. ~~Leonard’s~~Ekman ~~resignation~~meets ~~was~~the ~~not~~requirements ~~the~~for ~~result~~independence ofand ~~any~~financial ~~disagreement~~literacy ~~with~~of usaudit oncommittee ~~any~~members ~~matter~~under ~~relating~~the toapplicable ~~our~~listing ~~operations,~~standards ~~policies~~of orThe ~~practices,~~NASDAQ orStock ~~regarding~~Market LLC and the ~~general~~Securities ~~direction~~Exchange Act of ~~our~~1934, ~~company~~as amended.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 7, 2011
		ARYx THERAPEUTICS, INC.
	By:	/s/ David Nagler
		David Nagler
		Vice President, Corporate Affairs and Secretary

Dated: February 17, 2011

3ARYx THERAPEUTICS, INC. By: /s/ David Nagler David Nagler Vice President, Corporate Affairs and Secretary

Filing Compare · ARYx Therapeutics, Inc.